智通财经编辑 | 谢欣 2025年年末的罗永浩科技创新分享大会上，罗永浩迟到40多分钟才出现在讲台。随后他在微博上提及自 己患有ADHD（注意缺陷与多动障碍）一事。该疾病由此再引发关注。ADHD对一些家长来说更不陌 生，治疗该病的哌甲酯类药物一度被俗称为"聪明药"，甚至在未严格确诊的群体中也受到追捧。 当下该领域亦有新进展。 1月6日，爱科百发宣布，其复方氯丝右哌甲酯胶囊（商品名：爱智达）获国家药监局批准，适用于治疗 6岁及6岁以上ADHD患者。这也是爱科百发首个进入商业化阶段的产品。 据爱科百发招股书，该复方制剂包含30%速释右哌甲酯（d-MPH）和70%丝右哌甲酯（SDX，右哌甲酯 前药）。通过胃肠道吸收后，丝右哌甲酯转化为右哌甲酯。这一设计可以全天逐步释放右哌甲酯，通过 右哌甲酯快速控制症状，并通过丝右哌甲酯延长治疗时间，实现稳定的全天ADHD症状控制。 该复方制剂由Commave研发，2021年3月在美获批（商品名：AZSTARYS）。同年12月，爱科百发以总 价1.055亿美元获得该药的大中华区权益。 源：视觉中国 智通财经记者 | 陈杨 | 药品名 | 初始剂量(mg)及加量方法 | | 用药频率 ...

本文最早发布于 2021 年。文章发表后，我收到了许多正面反馈，不少朋友都说是因为读到了这篇文章才知道了 ADHD，甚至走进医院，获得 了医生的帮助和诊疗。 而在 2025 年的罗永浩科技创新发布会后，老罗发布了一条微博，表达了自己因为 ADHD 而拖延和患得患失，最终影响了直播效果的感慨。 ADHD 因此再度登上微博热搜，又一次成为公众话题。 因此，我在补充了新信息、新内容后重推本文，希望你可以了解 ADHD，也希望能帮助更多疑似或已经确诊为 ADHD 的朋友们走出困境。 也许你在工作和生活中时常遇到这样的问题：精神不集中，很难长时间只做某项工作，非常容易分神；情绪不稳定，对于他人的行动没有耐心，易怒；严 重拖延，经常踩着死线甚至跨过死线完成项目。如果你在分神、冲动或拖延的时候内心充满了自责与困扰，但就是无法控制自己的注意力和行动力，那你 有可能和我一样，也是 ADHD 患者。 在 2016 年的「罗辑思维读书会」上，罗永浩分享了一本冷门书籍《分心不是我的错》，这是 ADHD 这个概念在国内声量最大的一次曝光和讨论。事实 上，全球大约有 6% 到 8% 的儿童都或轻或重地患有 ADHD，其中一些可以在成长过 ...

以下文章来源于果壳 ，作者见文末 果壳 . 创业者的隐形挑战：罗永浩的ADHD坦白 。 文 ｜ 窗敲雨、透明 编辑 ｜ 李小葵 来源｜ 果壳（ID:Guokr42） 封面来源 ｜ IC Photo 2025年最后一天，还出了热点新闻。 12月30日的发布会，罗永浩又又又迟到了。上场后他表示"发生了一些事情，向大家道歉。后续会发文解释一下，希望大家理解"。于是今早网友们醒来，看 到了这样一条微博。 科学和技术，是我们和这个世界对话所用的语言。 罗永浩说的问题，都和ADHD有关吗？ 先看罗永浩微博中的第1点"发布会没有彩排"和第2点"幻灯片做不完"——这些符合成人ADHD的典型症状。 不同于儿童ADHD突出的多动症状， 成人ADHD最显著的表现通常是注意缺陷。 注意力不集中，如阅读、写作和做事时注意力难以持续，导致患者很难坚 持做完一件事情，尤其是对于注意力维持要求较高的任务或工作（如完成有一定难度的备课、写作、制作幻灯片等），因而经常回避、拖延、草率应付或不 能完成任务。"幻灯片做不完"有可能是由于这样的原因。 同时， 成人ADHD患者存在明显的执行功能障碍 ，主要表现为计划、组织安排工作、学习和家务困难，安排 ...

12月30日晚间，罗永浩2025年度科技创新分享大会在上海举行。根据预告，大会应于当日19时进行，不 过罗永浩本人并未准时现身，而是迟到了40多分钟后才出现在讲台。 随后罗永浩宣布全额退还300至1000元不等的门票，并鞠躬道歉称"要写认罪书"。深夜，罗永浩进一步 在社交账号自曝，迟到与患病十几年的ADHD（注意缺陷与多动障碍）相关。 根据《中国成人注意缺陷多动障碍诊断和治疗专家共识（2023年版）》，中国成人ADHD患病率约为 3%。目前对ADHD的治疗主要包括药物治疗、心理治疗和行为训练等，其中，药物治疗是最有效的方 法之一，可以缓解多动症的核心症状。 记者在采访中了解到，罗永浩在微博中提到的药物专注达，就是盐酸哌甲酯缓释片，其也是ADHD的一 线治疗药物。在过去20年，国内市场仅强生制药一家企业拥有该品种的进口药品批准文号。 浙江省人民医院儿科主任医师朱海峤是长期从事ADHD诊疗领域的专家，其在接受《每日经济新闻》记 者电话采访时表示，截至目前，还没有找到一种能够在短期内治愈ADHD的方法。ADHD作为一种慢性 病，需要长期管理和综合性治疗。在国内现有治疗条件下，尚无更优的替代药物。 罗永浩自曝患多动症 ...

每经记者｜甄素静 每经编辑｜何小桃 张益铭 12月30日晚间，罗永浩2025年度科技创新分享大会在上海举行。根据预告，大会应于当日19时进行，不过罗永浩本人并未准时现身，而是迟到了40多分钟 后才出现在讲台。 根据《中国成人注意缺陷多动障碍诊断和治疗专家共识（2023年版）》，中国成人ADHD患病率约为3%。目前对ADHD的治疗主要包括药物治疗、心理 治疗和行为训练等，其中，药物治疗是最有效的方法之一，可以缓解多动症的核心症状。 记者在采访中了解到，罗永浩在微博中提到的药物专注达，就是盐酸哌甲酯缓释片，其也是ADHD的一线治疗药物。在过去20年，国内市场仅强生制药一 家企业拥有该品种的进口药品批准文号。 随后罗永浩宣布全额退还300至1000元不等的门票，并鞠躬道歉称"要写认罪书"。深夜，罗永浩进一步在社交账号自曝，迟到与患病十几年的ADHD（注 意缺陷与多动障碍）相关。 浙江省人民医院儿科主任医师朱海峤是长期从事ADHD诊疗领域的专家，其在接受《每日经济新闻》记者电话采访时表示，截至目前，还没有找到一种能 够在短期内治愈ADHD的方法。ADHD作为一种慢性病，需要长期管理和综合性治疗。在国内现有治疗条件下， ...

*ADHD全称为Attention Deficit Hyperactivity Disorder，翻译为注意缺陷多动障碍或注意力缺陷过动症， 中文语境下常叫多动症。ADHD是一种神经发育障碍，在美国《精神障碍诊断与统计手册》第五版 （DSM-5）中，将ADHD划分为注意力不集中型ADHD-PI（难以维持注意力、分心、健忘）和多动-冲 动型ADHD-HI（过度的、不适宜的活动和行为冲动）以及混合型ADHD-C)同时满足注意力不集中和多 动-冲动的症状标准)。 *根据《注意缺陷多动障碍早期识别、规范诊断和治疗的儿科专家共识（2020年版）》统计显示，我国 儿童多动症患病率高达6.26%，患者人数约为2300万人，但临床就诊率却仅约10%。部分患者在儿童期 出现的病症可能会持续至成年，中国成人多动症患病率约为3%。 1、"左右互搏" 今年九月，我在小红书上发起了一个招募，希望能找到几位和我一样30岁以上、未婚、成年后确诊 ADHD的女性患者，成立一个互助小组，来交流各自面对ADHD的经验和问题。一时间收到了很多回 应，很多人希望能放宽条件，但我还是坚持了这些近乎苛刻的条件，在多次沟通后，我最终成功获得了 4位志趣相 ...

Core Insights - The first domestic generic version of "Zhuanzhu Da" has been officially launched in early September, produced by Lifang Pharmaceutical, with the generic name "Liyoujia" [1] - The original drug, methylphenidate extended-release tablets, is a first-line treatment for ADHD, developed by Johnson & Johnson, and has been in use in China since 2005 [1][2] - The patent for "Zhuanzhu Da" expired in 2012, but due to technical barriers, the first generic drug was only launched this year [1][2] - The launch of "Liyoujia" is expected to alleviate the supply shortage of the original drug and enhance production autonomy [1][3] Industry Overview - ADHD, or Attention Deficit Hyperactivity Disorder, affects approximately 23 million children in China, with a prevalence rate of 6.26% among children, but only about 10% of patients seek clinical treatment [2] - The adult ADHD prevalence rate in China is around 3% [2] - The demand for ADHD medication is significant due to the large patient population in China [2] Market Dynamics - There have been reports of drug shortages for "Zhuanzhu Da" in some regions, prompting the manufacturer, Xi'an Janssen, to enhance global production capacity and shift packaging operations to China by Q2 2025 [3] - "Liyoujia" utilizes advanced three-layer permeation pump technology for precise controlled release, ensuring stable efficacy throughout the day [3] Regulatory Environment - Methylphenidate is classified as a first-class psychotropic drug in China, subject to strict regulations throughout its production and distribution [4][5] - Only qualified physicians can prescribe this medication, and patients must present a red prescription to obtain it [5] - The drug's mechanism of action involves regulating specific neurotransmitter systems in the brain, improving cognitive and behavioral symptoms in patients with attention deficits [5] Social Implications - The term "smart drug" has been misleadingly used in some circles, leading to misuse among non-ADHD patients, which can result in addiction and other serious side effects [6][7] - Recent initiatives by multiple government departments aim to prevent the misuse of psychotropic drugs among youth, emphasizing the importance of adhering to medical advice [7]

Core Insights - The article discusses the introduction of a generic version of methylphenidate extended-release tablets, named "Liyoujia," by Lifan Pharmaceutical, which is expected to disrupt the market currently dominated by the imported drug "Zhuanzhuda" [1][4]. Group 1: Market Overview - Approximately 20 million children and adolescents in China are affected by Attention Deficit Hyperactivity Disorder (ADHD), with a prevalence rate of 6.26% among children [1][2]. - The original drug "Zhuanzhuda" has been the only approved methylphenidate extended-release product in China for the past 20 years, leading to supply shortages and high prices [1][3]. - The sales of methylphenidate extended-release tablets in domestic sample hospitals reached approximately 350 million yuan in 2023, with a projected increase to about 430 million yuan in the first three quarters of 2024 [3]. Group 2: Product Launch and Impact - Lifan Pharmaceutical's "Liyoujia" is the first domestic generic version of methylphenidate extended-release tablets, which is expected to alleviate supply issues and reduce costs for patients [1][4][5]. - The pricing of "Liyoujia" is set at approximately 15.3 yuan per tablet, which is about 20% lower than the original drug priced at around 19 yuan per tablet [5][7]. - The launch of "Liyoujia" is seen as a significant milestone in the ADHD treatment market, as it is expected to meet the growing demand and provide a more stable supply of medication [4][5]. Group 3: Regulatory and Market Dynamics - The production and sales of methylphenidate extended-release tablets require approval from the National Medical Products Administration, with plans for production volume to be reported in October [6]. - Lifan Pharmaceutical's "Liyoujia" is not subject to centralized procurement due to its classification as a first-class psychotropic drug, which is expected to stabilize its pricing in the market [7][8]. - The company has established a unique advantage in the production of controlled-release formulations, which is critical for the effective management of ADHD [7].

Core Viewpoint - Lifan Pharmaceutical has launched its first generic drug, Liyoujia Methylphenidate Sustained-Release Tablets, breaking the market monopoly of Johnson & Johnson's product for ADHD treatment in China [1][2]. Group 1: Product Launch - Lifan Pharmaceutical's Liyoujia Methylphenidate Sustained-Release Tablets are now available for sale, targeting the ADHD treatment market [1]. - The product's pricing is approximately 20% lower than the imported original drug, and it is eligible for insurance reimbursement [1]. Group 2: Market Context - For the past 20 years, Johnson & Johnson was the sole provider of this medication in China, marketed as "Zhuanzhuda" [1]. - The demand for Methylphenidate Sustained-Release Tablets has been rapidly increasing, with sales in domestic sample hospitals reaching approximately 350 million yuan in 2023 and projected to grow to about 430 million yuan in the first three quarters of 2024 [1]. Group 3: Supply and Regulatory Aspects - The production and sales of Liyoujia require approval from the National Medical Products Administration (NMPA) [2]. - The expected production volume for next year will be reported to the provincial drug administration in October, with a final approval from the NMPA, and an additional opportunity for volume increase in May [2]. Group 4: Supply Issues - There have been frequent shortages of the original drug over the past year, with multiple notifications from hospitals regarding temporary suspensions of the product [1].

Core Viewpoint - The launch of "Liyoujia," a generic version of methylphenidate extended-release tablets by Lifan Pharmaceutical, breaks the monopoly of Johnson & Johnson's "Zhuanzhuda" in the ADHD treatment market in China, addressing the supply issues faced by patients [1][8]. Group 1: Market Demand and Supply - Approximately 20 million children and adolescents in China suffer from ADHD, with a prevalence rate of 6.26% among children, but only about 10% seek treatment [3][4]. - The sales of methylphenidate extended-release tablets reached approximately 350 million yuan in 2023 and are projected to grow to about 430 million yuan in the first three quarters of 2024 [4]. - The original drug "Zhuanzhuda" frequently experiences supply shortages due to strict regulations and high raw material costs, leading to patient anxiety regarding medication availability [1][5][6]. Group 2: Product Comparison and Pricing - "Liyoujia" is priced approximately 20% lower than the original drug, with the original priced at about 19 yuan per tablet and "Liyoujia" at approximately 15.3 yuan per tablet [8][11]. - The production and sales of methylphenidate extended-release tablets require approval from the National Medical Products Administration, with plans for production volume to be reported in October [8][10]. Group 3: Regulatory Environment and Market Position - As a first-class psychotropic drug, "Zhuanzhuda" is subject to strict regulations, and its global demand has been increasing, which exceeds the production capacity of Johnson & Johnson [5][11]. - "Liyoujia" is not subject to centralized procurement due to its classification as a psychotropic drug, which is expected to stabilize its pricing in the market [11].